Companies /Healthcare

Humacyte Inc

NASDAQ: HUMA Biotechnology
$0.53
▼ $0.03 (−4.89%) today
Markets open · 2:35pm ET

HUMA at a Glance

Valuation
Market cap
$155.1M
Profitability
Revenue (TTM)
$2.4M
EPS (TTM)
$-0.45
Price
52-week range
$0 – $2
Street target
$1.64

Headquartered in Durham, NC Fiscal year ends December NASDAQ: HUMA humacyte.com

About Humacyte

Humacyte, Inc. (Nasdaq: HUMA) is a commercial-stage biotechnology platform company developing and manufacturing universally implantable, bioengineered human tissues at commercial scale.

Its lead product, Symvess, is an acellular tissue engineered vessel (ATEV). The FDA approved it in December 2024 for adults who need a vascular conduit for extremity arterial injury, when urgent revascularization is needed to avoid limb loss and autologous vein graft is not feasible. Symvess generates the company's product revenue and is sold to hospitals; 49 hospitals had ordered it as of September 30, 2026.

The ATEV is also in late-stage clinical development for:
- Arteriovenous (AV) access in hemodialysis, with a supplemental BLA planned for November 2026 based on the V007, V012 and a third Phase 3 study.
- Peripheral artery disease.

The company's coronary tissue engineered vessel (CTEV) has entered a first-in-human Phase 2a study in coronary artery bypass grafting. Preclinical programs include pediatric heart surgery, type 1 diabetes, and other cell and tissue applications.

Regulatory designations:
- The 6mm ATEV for dialysis access was the first product candidate to receive RMAT designation and also holds Fast Track designation.
- The vascular trauma and advanced PAD indications also hold RMAT designations.
- The ATEV has priority designation for vascular trauma from the U.S. Secretary of Defense. Updated

HUMA Coverage

Frequently Asked Questions

What does Humacyte do?

Humacyte, Inc. (Nasdaq: HUMA) is a commercial-stage biotechnology platform company developing and manufacturing universally implantable, bioengineered human tissues at commercial scale. Its lead product, Symvess, is an acellular tissue engineered vessel (ATEV).

What is the HUMA stock price target?

The Wall Street consensus 12-month price target for HUMA is $1.64.